Adoptive Transfer of Tumor-infiltrating Lymphocytes in Melanoma: a Viable Treatment Option

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2018 Oct 5

PMID 30285902

Citations 107

Authors

Maartje W Rohaan

Joost H van den Berg

Pia Kvistborg

John B A G Haanen

Affiliations

Soon will be listed here.

Abstract

The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered.

Citing Articles

Integrative analysis of DNA methylation and gene expression in skin cutaneous melanoma by bioinformatic approaches.

Zhang L, Peng Y, Huang S, Zhong L Arch Dermatol Res. 2025; 317(1):545.

PMID: 40067504 PMC: 11897118. DOI: 10.1007/s00403-025-03863-2.

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.

Mehta A, Motavaf M, Nebo I, Luyten S, Osei-Opare K, Gru A J Clin Med. 2025; 14(4).

PMID: 40004731 PMC: 11856346. DOI: 10.3390/jcm14041200.

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered.

Chen P, Li K, Chen J, Hei H, Geng J, Huang N Transl Oncol. 2025; 53:102319.

PMID: 39938403 PMC: 11869540. DOI: 10.1016/j.tranon.2025.102319.

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.

Into the Future: Fighting Melanoma with Immunity.

Corica D, Bell S, Miller P, Kasperbauer D, Lawler N, Wakefield M Cancers (Basel). 2024; 16(23).

PMID: 39682188 PMC: 11640241. DOI: 10.3390/cancers16234002.

References

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

Ellebaek E, Iversen T, Junker N, Donia M, Engell-Noerregaard L, Met O . Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012; 10:169. PMC: 3514199. DOI: 10.1186/1479-5876-10-169. View

Yannelli J, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L . Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer. 1996; 65(4):413-21. DOI: 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#. View

Idorn M, Straten P, Marie Svane I, Met O . Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. Methods Mol Biol. 2016; 1428:261-76. DOI: 10.1007/978-1-4939-3625-0_17. View

Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J . Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012; 18(24):6758-70. PMC: 3525747. DOI: 10.1158/1078-0432.CCR-12-1177. View

Retel V, Steuten L, Mewes J, van Harten W . Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients. Value Health. 2016; 17(7):A640. DOI: 10.1016/j.jval.2014.08.2307. View

Ye Q, Song D, Poussin M, Yamamoto T, Best A, Li C . CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2013; 20(1):44-55. PMC: 3947326. DOI: 10.1158/1078-0432.CCR-13-0945. View

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, De Plaen E . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995; 269(5228):1281-4. DOI: 10.1126/science.7652577. View

Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C . Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-1356. PMC: 5706778. DOI: 10.1056/NEJMoa1709684. View

10.

Goff S, Dudley M, Citrin D, Somerville R, Wunderlich J, Danforth D . Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016; 34(20):2389-97. PMC: 4981979. DOI: 10.1200/JCO.2016.66.7220. View

11.

Andersen R, Westergaard M, Kjeldsen J, Muller A, Pedersen N, Hadrup S . T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Cancer Immunol Res. 2018; 6(2):222-235. DOI: 10.1158/2326-6066.CIR-17-0467. View

12.

Donia M, Kjeldsen J, Andersen R, Westergaard M, Bianchi V, Legut M . PD-1 Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clin Cancer Res. 2017; 23(19):5779-5788. PMC: 7115919. DOI: 10.1158/1078-0432.CCR-16-1692. View

13.

Besser M, Shapira-Frommer R, Itzhaki O, Treves A, Zippel D, Levy D . Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013; 19(17):4792-800. DOI: 10.1158/1078-0432.CCR-13-0380. View

14.

Tarhini A, Edington H, Butterfield L, Lin Y, Shuai Y, Tawbi H . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705. PMC: 3912016. DOI: 10.1371/journal.pone.0087705. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Tran E, Turcotte S, Gros A, Robbins P, Lu Y, Dudley M . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344(6184):641-5. PMC: 6686185. DOI: 10.1126/science.1251102. View

17.

Chandran S, Somerville R, Yang J, Sherry R, Klebanoff C, Goff S . Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017; 18(6):792-802. PMC: 5490083. DOI: 10.1016/S1470-2045(17)30251-6. View

18.

Schluns K, Kieper W, Jameson S, Lefrancois L . Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol. 2001; 1(5):426-32. DOI: 10.1038/80868. View

19.

Luke J, Flaherty K, Ribas A, Long G . Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8):463-482. DOI: 10.1038/nrclinonc.2017.43. View

20.

Foley K, Nishimura M, Moore T . Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Res. 2018; 28(3):171-184. PMC: 5912975. DOI: 10.1097/CMR.0000000000000436. View